The androgen synthesis inhibitor abiraterone increases the survival of men with metastatic prostate cancer; however, existing clinical trials consistently over-represent Caucasian men. Here, Andrew Armstrong, MD, of Duke University, Durham, NC, presents the findings of his recent study, which aimed to include equal numbers of African American and Caucasian men to compare responses to abiraterone. He explains how African American men responded better to the treatment, showing an improved PSA response compared to the Caucasian men; and also mentions his goals for future genotyping studies, which would illuminate the reasons behind these differences. In addition, Dr Armstrong discusses why African American men are often under-represented in clinical trials, and how he worked to engage the community in order to build this patient base. This interview was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.
African Americans with prostate cancer respond better to abiraterone than Caucasians
